title: [What's new in internal medicine?].
abstract: This article focuses on current trends in various autoimmune diseases of interest for the dermatologist. In the antiphospholipid syndrome, many news: better characterization of the severe disease, involvement of the mTOR pathway in the vasculopathy-induced renal disease, and diversification of the therapeutic approaches: use of mTOR inhibitors and several biologics, new various antiplatelet and anticoagulants. In dermatomyositis, new autoantibodies are better characterized with a good correlation with clinical disease; the results of a large study on genetic predisposition to the disease are available. There are also some therapeutic innovations in systemic sclerosis: benefit of rituximab that seems well tolerated, the results of a large controlled European study about aggressive immunoablative chemotherapy followed by autologous stem cells have just been published, intralesional stem cells injections in the fingers of sclerodactylic patients. Finally, news in celiac disease that is constantly increasing and whose mild forms often have cutaneous manifestations, leading to diagnosis.
authors.affiliation: Clinique de dermatologie, hôpitaux universitaires de Genève, rue Gabriellet Perret-Gentil 4, CH-1211 Genève, Suisse. Electronic address: emmanuel.laffitte@hcuge.ch.
authors.forename: E
authors.initials: E
authors.lastname: Laffitte
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000276:immunology; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D001688:Biological Products / Q000627:therapeutic use; D002446:Celiac Disease / Q000235:genetics / Q000276:immunology; D003131:Combined Modality Therapy; D020022:Genetic Predisposition to Disease; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007388:Internal Medicine / Q000639:trends*; D012595:Scleroderma, Systemic / Q000628:therapy; D012871:Skin Diseases / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D019851:Thrombophilia / Q000209:etiology; D014182:Transplantation, Autologous
chemical_list: D000925:Anticoagulants; D018501:Antirheumatic Agents; D001323:Autoantibodies; D001688:Biological Products; D007166:Immunosuppressive Agents
keywords: Antiphospholipidssyndrom; Coeliac disease; Dermatomyosite; Dermatomyositis; Maladie cœliaque; Sclerodermia; Sclérodermie; Syndrome des antiphospholipides